This is a working overview of RP-HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-27 and is reviewed periodically as new material appears.
Reconstitution is the process of adding a liquid to a lyophilized peptide so that the dried material dissolves into solution. Lyophilization removes water from a frozen peptide preparation under reduced pressure, leaving a porous solid or powder. The dried form often has greater long-term stability than a liquid because hydrolysis and oxidation are slowed. In laboratory work, reconstitution is usually the first step before dilution, analysis, or further experiments. The result is a stock solution whose concentration depends on the volume of solvent added and the amount of peptide in the vial.
Solvent choice depends on the peptide's sequence, charge, and solubility profile. Sterile water is common for freely soluble peptides, while aqueous buffers or dilute acid or base may be needed for others. Some sequences contain hydrophobic regions that resist water alone and require a small amount of organic co-solvent. The solvent's pH can affect charge state, aggregation, and stability. Because peptides vary widely, no single universal reconstitution liquid exists, and suppliers often provide a recommended solvent based on testing of a specific lot or sequence.
Once a peptide is dissolved, water becomes a medium for hydrolysis, oxidation, and deamidation. Dry powders often tolerate ambient shipping better than liquid solutions, but the exact stability profile depends on sequence and formulation. Refrigerated storage near 2 to 8 degrees Celsius or frozen storage at minus 20 or minus 80 degrees Celsius is common in laboratories. Repeated freeze-thaw cycles can promote aggregation, precipitation, or loss of activity. Dividing a solution into single-use aliquots before freezing can reduce the number of temperature cycles.
Aseptic technique is used when a reconstituted solution must remain free of microbial contamination. Work surfaces, gloves, and instruments are cleaned, and the septum of a vial is disinfected before solvent is added. A venting needle or pressure equalization can prevent aerosol formation and pressure buildup. Bacteriostatic water contains an antimicrobial preservative, but preservatives can interfere with some assays or alter peptide behavior. Sterile filtration may be used when a formulation cannot be heat sterilized or when particulates must be removed.
| Property | Value | Notes |
|---|---|---|
| Physical state before solvent | Lyophilized powder or cake | Freeze-drying removes water under vacuum and leaves a porous solid. |
| Common reconstitution liquid | Sterile water or aqueous buffer | Compatibility depends on peptide sequence, charge, and pH requirements. |
| Typical solution pH | pH 3 to 7 | Acidic or slightly acidic conditions are common; some peptides need other ranges. |
| Appearance after dissolution | Clear to slightly opalescent solution | Cloudiness can indicate incomplete dissolution, aggregation, or undissolved excipients. |
| Concentration basis | Mass of peptide per volume of solvent | Label mass may include counterions or salts, so peptide content can differ. |
After a dried peptide is dissolved, the resulting solution is treated as a distinct material with its own stability profile. Temperature, pH, ionic strength, and peptide concentration all influence how long the solution remains suitable for its intended laboratory use. Some sequences are prone to oxidation, deamidation, or aggregation. Because these processes vary widely, no single storage condition applies to every peptide. Buffer composition and light exposure can also shift degradation rates.
Aseptic technique matters when the solution will contact cells or biological reagents. Working in a clean environment, using sterile liquids and containers, and minimizing open-vial time reduce the chance of microbial contamination. Filtration through a sterile filter can remove particles and microorganisms, but some filters adsorb peptides and some peptides are retained by certain membrane materials. Compatibility between the peptide, solvent, and filter should be checked when recovery is critical.
The choice of liquid depends on peptide sequence, counterion content, and intended analysis. Water is sufficient for many hydrophilic peptides, while hydrophobic sequences may need a small amount of organic solvent or a buffer. pH can affect charge, solubility, and stability, so the target value is usually selected for the specific peptide. Exact laboratory protocols vary by supplier and application, and no single solvent reliably works for every different peptide.
Reconstitution involves considerably more than simply adding liquid. The solid must wet completely, and gentle mixing should avoid foaming, which can denature some peptides. Insoluble particles may indicate incomplete dissolution, aggregation, or insoluble excipients. The resulting concentration is calculated from the weighed peptide mass and the final volume, not from the volume of liquid added alone. Because peptides can adsorb to surfaces, container material and transfer steps can influence recovery, especially at low concentrations.
=== The beginning of antibody imaging === Owing to their high affinity and specificity, antibodies have been considered as suitable vehicles for imaging and therapeutics, since the beginning of the 20th Century. The first radiolabelled antibodies were used in the early 1950s and got used for cancer therapy, but it took roughly two more decades before it was demonstrated that they target human tumour associated antigens in cancer patients. Due to the hybridoma technology in 1975, monoclonal (murine) antibodies could easily be produced in practical amounts, consequently the number of studies increased drastically. However, these types of antibodies turned out to be quite troublesome, due to the triggering of the human anti-murine antibody response. Consequently chimeric, humanised and human monoclonal antibodies have been created, produced and get used nowadays. Owing to the high molecular weight of antibodies and the Fc domain of the antibody, a slow clearance from the blood and non-target tissue occurs, which results in low tumour-to-blood and tumour-to-muscle ratios. Because of this, antibodies which are going to be used for imaging purposes need to be labelled with radionuclides that have a long half-life, which increases the radiation dose to the patient. This consequently encouraged the development of lower molecular weight antibodies and resulted in the development of minibodies, diabodies, single chain variable fragments (scFv) and single domain fragments (Fv).
=== Third representation === Given uncontrolled flow rate or varied solvent composition, another representation was designed such that a different heating source and control system would allow for partial vaporization. Two different heating methods were combined because one is capable of more rapid response time while the other is slower. This combination allows the third representation of vaporizer to handle fluctuations in flow rate coming of the LC column.
== Function == LepA is suspected to improve the fidelity of translation by recognizing a ribosome with mistranslocated tRNA and consequently inducing a back-translocation. By back-translocating the already post-transcriptionally modified ribosome, the EF-G factor capable of secondary translocation. Back-translocation by LepA occurs at a similar rate as an EF-G-dependent translocation. As mentioned above, EF-G's structure is highly analogous to LepA's structure; LepA's function is thus similarly analogous to EF-G's function. However, Domain IV of EF-G has been shown through several studies to occupy the decoding sequence of the A site after the tRNAs have been translocated from A and P sites to the P and E sites. Thus, domain IV of EF-G prevents back-movement of the tRNA. Despite the structural similarities between LepA and EF-G, LepA lacks this Domain IV. Thus LepA reduces the activation barrier between Pre and POST states in a similar way to EF-G but is, at the same time, able to catalyze a back-translocation rather that a canonical translocation.
Sources: en.wikipedia.org
Tetrahydrofuran (THF), or oxolane, is an organic compound with the formula (CH2)4O. The compound is classified as heterocyclic compound, specifically a cyclic ether. It is a colorless, water-miscible organic liquid with low viscosity. It is mainly used as a precursor to polymers. Being polar and having a wide liquid range, THF is a versatile solvent. It is an isomer of another solvent, butanone.
Prusiner of California named the prion, and thought that the protein did not require DNA to be made; the Institute of Molecular Systems Biology of ETH Zurich, and Charles Weiss mann, who looked for a section of mRNA that could make the protein, and in 1985 found a possible section of DNA; husband and wife, Harry Baker and Ros Ridley of the MRC in London discovered in 1989 that a genetic mutation could cause the prion to be made; seventeen possible genetic mutations were found in total in the UK; children treated with human growth hormone were found, in May 1985, to have CJD; Michael Preece of the UCL Great Ormond Street Institute of Child Health in London; more cases were found in France in 1992; scrapie in sheep; remains of sheep, in cattle feed caused BSE, which was discovered in 1986; Ray Bradley, head of BSE research at the Central Veterinary Laboratory; Graham Medley, a disease modeller at Imperial College, who looked at other modes of possible transmission, than contaminated animal feed; James Kirkwood, of the Institute of Zoology in London, and infection in the greater kudu; Gordon Hunter, veterinary researcher; Hamish Chalmers of Redesdale in Northumberland, and scrapie-resistant Swaledale sheep, which were bred at the Institute for Research on Animal Diseases (now the Pirbright Institute) at Compton, Berkshire; the amyloid beta protein of dementia, and research on marmosets. Narrated by Libby Purves, directed by John Bird, produced by Mike Johnstone, made by Langham Productions
Proline (symbol Pro or P) is an organic acid classed as a proteinogenic amino acid (used in the biosynthesis of proteins), although it does not contain the amino group -NH2 but is rather a secondary amine. The secondary amine nitrogen is in the protonated form (NH2+) under biological conditions, while the carboxyl group is in the deprotonated −COO− form. The "side chain" from the α carbon connects to the nitrogen forming a pyrrolidine loop, classifying it as a aliphatic amino acid. It is non-essential in humans, meaning the body can synthesize it from the non-essential amino acid L-glutamate. It is encoded by all the codons starting with CC (CCU, CCC, CCA, and CCG). Proline is the only proteinogenic amino acid which is a secondary amine, as the nitrogen atom is attached both to the α-carbon and to a chain of three carbons that together form a five-membered ring.
Sources: en.wikipedia.org
Reconstitution means adding a liquid to a dried peptide to form a solution. The dried material is usually a lyophilized powder or cake produced by freeze-drying. The resulting liquid is a stock solution that can be diluted or analyzed further.
Freeze-drying removes water and limits hydrolysis and oxidation during storage. The dried solid is generally more stable and easier to ship than a liquid. It also allows a defined amount of material to be sealed in a single vial.
No. Solubility depends on the amino acid sequence, charge, and hydrophobic content. Some peptides require buffer, dilute acid, dilute base, or a small amount of organic solvent. A supplier's recommended solvent is based on the specific peptide.
Storage time varies with peptide sequence, concentration, solvent, and temperature. No single duration applies to all peptides, and a clear solution can still degrade without a visible change.